NCT03728335 2026-03-13
Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
City of Hope Medical Center
Phase 2 Recruiting
City of Hope Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
Hitit University
City of Hope Medical Center
Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc.